Arbutus Biopharma Corp. (NASDAQ:ABUS) traded up 3.1% during mid-day trading on Thursday . The company traded as high as $4.05 and last traded at $3.97, with a volume of 83,391 shares trading hands. The stock had previously closed at $3.85.

A number of equities research analysts recently issued reports on the stock. Zacks Investment Research raised shares of Arbutus Biopharma Corp. from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a research note on Thursday, March 10th. Leerink Swann reaffirmed a “buy” rating and set a $12.00 price target on shares of Arbutus Biopharma Corp. in a research note on Thursday, May 5th. Chardan Capital began coverage on shares of Arbutus Biopharma Corp. in a research note on Monday, May 16th. They set a “sell” rating and a $3.25 price target on the stock. Finally, Wedbush reissued an “outperform” rating and issued a $20.00 target price on shares of Arbutus Biopharma Corp. in a research note on Friday, April 22nd. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $11.04.

The company’s market cap is $217.95 million. The company has a 50-day moving average of $3.72 and a 200-day moving average of $3.95.

Arbutus Biopharma Corp. (NASDAQ:ABUS) last released its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.20. On average, analysts forecast that Arbutus Biopharma Corp. will post ($1.49) earnings per share for the current fiscal year.

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.